The costs of prostatectomy for benign prostatic hyperplasia.
Using claims data for a 5% random sample of Medicare beneficiaries, we estimated the costs of surgical treatment for benign prostatic hyperplasia (BPH), including those related to the initial prostatectomy, the treatment of postsurgical complications, and reoperation within one year. We identified 14,480 men who underwent prostatectomy for BPH during 1986-1987, including 13,730 transurethral and 750 open procedures. Mean total inpatient costs (including all hospital charges and professional service fees) for these procedures were estimated to be $6,501 and $10,223, respectively. Among patients who underwent transurethral and open prostatectomy, we identified 938 (6.8%) and 39 (5.2%) individuals who had at least one readmission for postsurgical complications or reoperation. Total expected costs of transurethral and open prostatectomy, inclusive of readmissions for complications and reoperations within one year, were estimated to be $6,823 and $10,477, respectively. Our study indicates the economic burden represented by surgical treatment of BPH.
Weis
K A
KA
Center for Medical Effectiveness Research, Agency for Health Care Policy and Research, Rockville, MD 20857.
Epstein
R S
RS
Huse
D M
DM
Deverka
P A
PA
Oster
G
G
D000368:Aged; D000369:Aged, 80 and over; D003365:Costs and Cost Analysis; D005249:Fees and Charges; D006801:Humans; D008297:Male; D006278:Medicare; D010359:Patient Readmission / Q000191:economics; D011183:Postoperative Complications / Q000191:economics; D011468:Prostatectomy / Q000191:economics*; D011470:Prostatic Hyperplasia / Q000601:surgery*; D012086:Reoperation / Q000191:economics; D014481:United States